Document:

Exhibit 10.05

                                   AGREEMENT

Sparta Surgical Corporation ("Sparta") and Cordial, N.V. ("Coridal") agree to
the following:

1.   In consideration of Corida1's services to Sparta, including, but not
     limited to, consult and financial services performed, Sparta shall issue to
     Coridal, 350,000 shares Common Stock, par value $0.002, of Sparta Surgical
     Corporation on or before November 25, 1999. All shares shall have piggyback
     registration rights and Sparta shall register the 350,000 shares issued
     pursuant to this Agreement, and (ii) the 582,000 shares previously issued
     to Coridal by Sparta, all no later than March 1, 2000. It is agreed that
     none of Coridal's Common Stock in Sparta will participate in a Voting
     Trust.

2.   Sparta agrees to set up a segregated account for the $350,000 loan and
     further agrees that it shall use the funds pursuant to the attached Use of
     Proceeds. Prior to Spar withdrawal of funds, Coridal's representative shall
     be notified as funds are about to withdrawn from the segregated account and
     the representative will acknowledge writing approval of same.

3.   It is agreed that Coridal shall have an irrevocable option (the "Option")
     to purchase additional 500,000 shares of Common Stock of Sparta Surgical
     Corporation, at a price of $1.00 per share, exercisable within ten days
     from submission of due diligence material Coridal for Sparta's targeted
     acquisition of Home Med-Equip, Inc. or a comparable acquisition. The Option
     supercedes all previous options given to Coridal by Sparta purchase Sparta
     Common Stock.

4.   Joel S. Ratner will be recommended and nominated by Thomas F. Reiner to the
     Boar Directors of Sparta.

5.   In the event that Coridal exercises the Option and purchases the 500,000
     shares of Sparta as set forth in paragraph 3 above, Coridal agrees to
     convert the indebtedness evidenced by that certain promissory note dated
     November 3, 1999 into 350,000 shares.

This Agreement shall be in all respects governed by and construed and applied in
accordance with laws of the State of New York. The parties to this Agreement
consent to the jurisdiction the New York Courts. Arty modification of this
Agreement must be in writing signed by Parties hereto.

AGREED AND ACCEPTED THIS 3rd DAY OF NOVEMBER, 1999

By:                                          /s/  Thomas F. Reiner
   --------------------------------          -----------------------------------
   Coridal, N.V.                             Thomas F. Reiner, Chairman
                                             President, CEO
                                             Sparta Surgical Corporation

<PAGE>

                                   AGREEMENT
                                   ---------

In consideration of Spags Investment Group, N.V. ("Spags") making a $350,000
loan to Sparta Surgical Corporation ("Sparta") it is agreed to by the above
parties as to the following:

     1.   Sparta will repay the $350,000 on March 3, 2000 at 7% annual interest
          as evidence by an executed promissory note (the "Note").

     2.   The moneys when due will be paid by Sparta outside the United States.
          Sparta will pay Spags by wiring funds to the account from which the
          funds were originally sent to Sparta.

     3.   Any modification of this Agreement will be in writing. This Agreement
          shall be in all respects governed and construed and applied in
          accordance with the laws of the State of New York. The parties to this
          Agreement consent to the jurisdiction of the New York Courts.

     4.   Sparta and Spags agree that if Coridal, N.Y. purchases 500,000 shares
          of Sparta Common Stock, par value $0.002, at $1.00 per share ("Common
          Stock"), then Coridal will also convert its Note of $350,000 into
          350,000 shares of Sparta Common Stock at $1.00 per share.

AGREED THIS 3rd DAY OF NOVEMBER, 1999

                                                  /s/  Thomas F. Reiner
-------------------------------                   ------------------------------
Spags Investment Group, N.V.                      Sparta Surgical Corporation
                                                  By Thomas F. Reiner, Chairman
                                                  of the Board President and CEO

<PAGE>

                                     OPTION

In consideration of Coridal, N.Y. ("Coridal") securing a loan from Spags
Investment Group, N.Y. ("Spags") for Sparta Surgical Corporation ("Sparta"),
Sparta and Coridal agree to the following:

     1.   In consideration of services performed, Sparta shall issue to Coridal,
          350,000 shares of Common Stock, par value $0.002, of Sparta Surgical
          Corporation on or before November 25, 1999. All shares shall have
          piggyback registration rights and Sparta shall, if requested by
          Coridal, register Coridal's 350,000 shares, Coridal's 240,000 shares
          and Coridal's 342,000 shares of Common Stock no later than March 1,
          2000. It is agreed that none of Coridal's Common Stock in Sparta will
          participate in a Voting Trust.

     2.   Sparta agrees to set up a segregated account for the $350,000 loan and
          further agrees that it shall use the funds pursuant to the attached
          Use of Proceeds. Coridal's representative shall be notified as funds
          are about to be withdrawn from the segregated account and the
          representative will acknowledge in writing approval of same.

     3.   It is agreed that Coridal shall have an irrevocable option ("Option")
          to purchase 500,000 shares of Common Stock, par value $0.002, of
          Sparta Surgical Corporation exercisable on the following terms:

          (a)  That within ten days from submission of due diligence material to
               Coridal for Sparta's targeted acquisition of Home Med-Equip, Inc.
               or a comparable acquisition, Coridal can purchase 500,000 shares
               of the above referred to Common Stock for $500,000.

     4.   Joel S. Ratner will be recommended and nominated by Thomas F. Reiner
          to the Board of Directors of Sparta.

This Agreement, which supercedes the Agreement of August 30, 1999, shall be in
all respects governed by and construed and applied in accordance with laws of
the State of New York. The parties to this Agreement consent to the jurisdiction
of the New York Courts. Any modification of this Agreement will be in writing.

AGREED AND ACCEPTED THIS 3RD DAY OF NOVEMBER, 1999

By:                                         /s/  Thomas F. Reiner
   -------------------------------          ------------------------------------
   Spags Investment Group, N.V.             Thomas F. Reiner, Chairman
                                            President, CEO
                                            Sparta Surgical CorporationExhibit 10.06
                              CONSULTING AGREEMENT

     CONSULTING AGREEMENT made this 11th day of March 1999 (this "Agreement"),
by and between

     Sparta Surgical Corporation, a Delaware corporation (the "Company") with
     offices at Bernal Corporate Park, 7068 Koll Center Parkway - Suite 425,
     Pleasanton, California 94566

 and

     IGC of New York Corporation, or its assigns ("the Consultant").

WITNESSETH:

     Whereas, the Company and the Consultant (or an entity related to or under
     common control with the Consultant) have entered into various agreements
     which pertain to consulting services similar to those identified in this
     Agreement, including but not limited to those dated December 1, 1998,
     December 3, 1998, February 23, 1999 and March 4, 1999,

     Whereas, this agreement is intended to supersede and replace all of these
     prior agreements, together with any amendments thereto and any other
     agreements which may exist, whether written or oral, regarding the
     Consultant's (which shall include Howard Schuster or any entity with which
     Howard Schuster has any affiliation) performing consulting services on
     behalf of the Company,

     Whereas, the Company desires to retain the services of the Consultant as a
     consultant on a non-exclusive basis to render financial advise and
     assistance to the Company in connection with the Company's seeking,
     negotiating and choosing merger and acquisition candidates, an din
     connection with the Company's seeking financing, which financing shall be
     subject to the approval in all respects by the Company in its sole
     discretion, all upon the terms and conditions set forth in this agreement,
     and

     Whereas, the Consultant desires to accept said retention.

     Now, therefore, in consideration of the premises and mutual covenants
herein set forth and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties do hereby agree as
follows:

     Section 1. Term of Consultancy. The term of the consultancy with the
Consultant (the "Term") shall commence on the date hereof (the "Effective Date")
and continuing for a period of two (2) years unless otherwise terminated
pursuant to Section 3 of this Agreement. This Agreement shall be non-exclusive.

<PAGE>

     Section 2. Fees. During the Term, the Company shall pay to the Consultant
(or a party designated by the Consultant) the following fees, which amounts
shall be payable solely with respect to any transactions or financings as to
which the Consultant has acted as the introducing party to the Company:

a.   Upon the execution of this Agreement, the Company shall issue to the
     Consultant 300,00C warrants to purchase one share of the Company's common
     stock, $0.002 par value ("Common Stock") at a price of $0.95 per share. The
     warrants shall expire if not exercised within three (3) years and shall
     have piggyback registration rights with respect to any shares issued upon
     their exercise.

b.   In the event the Consultant introduces the Company to a source of private
     placement financing, upon the closing and funding of such financing the
     Consultant shall be paid an amount equal to the following:

     Percentage of amount raised                     Type of Financing
     ---------------------------                     -----------------
                4%                                   Senior Secured Debt
                6%                                   Mezzanine/Subordinate Debt
                8%                                   Private Equity

     In addition, the Consultant shall, upon the closing and funding of a
     private placement financing in the amount of $10,000,000, receive 500,000
     warrants to purchase one share of the Company's Common Stock at a price of
     $0.95 per share in the event the Consultant introduces a source of such
     private placement. Consultant shall receive a lesser amount of warrants in
     the event a lesser amount of private placement funding is located, closed
     and financed, which amount shall be determined on a pro rata basis (for
     example, in the event $1,000,000 in private placement financing were
     located by the Consultant, which financing closes and is funded, the
     Consultant would be entitled to receive 50,000 warrants), provided however
     that a total of not more than 500,000 warrants shall be issued pursuant to
     this section. The warrants shall expire if not exercised within three (3)
     years of their issuance and shall have piggyback registration rights with
     respect to any shares issued upon their exercise.

c.   In the event the Consultant introduces the Company to a source of senior
     secured debt, mezzanine/subordinated debt or private equity bridge
     financing in an amount of at least $500,000, which financing closes and is
     funded on or before March 30, 1999, upon the closing and funding of such
     financing, in addition to the amounts owing under subparagraph b of this
     Section 2, the Consultant shall be paid $8,000 per month, in the form of
     equal monthly installments over the following twenty-four (24) month
     period, provided, however, that in the event a secondary public offering
     has not been completed and funded, through an underwriter introduced by the
     Consultant to the Company, resulting in net proceeds to the Company in an
     amount of not less than $10,000,000 (the "Secondary Offering"), on or
     before August 31, 1999, the Company's obligation to make such monthly
     payment shall cease on such date.

                                       2

<PAGE>

     In the event the Consultant introduces the Company to a target for any
     mergers or acquisitions which mergers or acquisitions are completed by the
     Company and which result in the Company's completing a Secondary Offering
     which results in the Company's receiving net proceeds in the amount of at
     least $10,000,000 the Consultant shall thereafter be retained, on a
     non-exclusive basis, as a consultant to assist the Company in locating and
     evaluating additional merger and acquisition opportunities for a period of
     twenty four months thereafter (the "Post-Offering Consulting Period"). In
     the event the Consultant is retained to act as a non-exclusive consultant
     during the Post-Offering Consulting Period pursuant to this subsection, the
     Consultant shall receive the following compensation for such services: (i)
     $100,000 at the time the Post-Offering Consulting Period commences; (ii)
     500,000 warrants to purchase one share of the Company's Common Stock at a
     price of $0.95 per share (which warrants shall expire if not exercised
     within three (3) years of their issuance and shall have piggyback
     registration rights with respect to any shares issued upon their exercise)
     (iii) $12,500 per month in the form of equal monthly installments over the
     twenty-four (24) month period comprising the Post-Offering Consulting
     Period.

     Section 3. Termination. This Agreement may be terminated under the
following circumstances:

a.   This Agreement may be terminated by the Consultant at any time upon ten
     days' written notice.

b.   The Company may terminate the agreement at any time for Cause following ten
     days' prior written notice. For purpose of this Agreement, "Cause" shall
     mean: (1) negligence of the Consultant in the performance of the duties
     hereunder, or (2) the commission of any felony by the Consultant.

     Section 4. Confidential Information. The Consultant expressly covenants and
agrees that it will not at any time, during or after the Term, directly or
indirectly, use or permit the use of any confidential information of or relating
to the Company and will not divulge such confidential information to any person,
firm, corporation, or other entity whatsoever except as is necessary for the
performance of duties as consultant to the Company under the terms of this
Agreement. In the event the Consultant is required by the court to divulge
information about the Company (or is requested to do so in any legal
proceeding), the Consultant hereby agrees to provide the Company with prompt
written notice of such request or requirement in order to enable the Company to
seek an appropriate protective order or other remedy, and to otherwise consult
with the Company with respect to taking steps to resist or narrow the scope of
such request or legal process. Any information which (i) is or becomes known to
the public without breach by the Consultant of any of the terms hereof or of the
common law duties of the Consultant, (ii) is developed independently by the
Consultant without reference to any confidential information, or (iii) is or

                                        3

<PAGE>

becomes available to the Consultant from sources outside the Company, is
not bound by a confidentiality agreement with the Company prohibiting such
disclosure, and shall not be deemed to be confidential information.

     Section 5. General.

a.   Applicable law. This Agreement shall, in all respects, be governed by the
     laws of the State of California, without giving effect to conflicts of law
     principles. The parties consent to the jurisdiction of a court of proper
     jurisdiction located in Alameda County, State of California for resolution
     of all disputes relating to or arising under this Agreement.

b.   Survival. Except as provided herein, the parties hereto agree that the
     covenants in Section 5 hereof shall survive the termination of this
     Agreement.

c.   Indemnification. The Company hereby agrees to indemnify and hold the
     Consultant harmless from and against any and all costs, expenses (including
     attorney's fees), liabilities, losses, damages, fines, penalties,
     judgements and amounts paid in settlement ("Losses"), that are incurred or
     suffered by the Consultant which arise from the Consultant's services to
     the Company or services performed at the request of the Company.
     Notwithstanding the foregoing, the Company shall not be required to
     indemnify the Consultant in respect of losses or damages arising from
     negligence or willful misconduct of the Consultant.

d.   Modifications or Amendments. No amendment, change or modification of this
     document shall be valid unless in writing and signed by all parties hereto.

e.   Waiver. No reliance upon or waiver on one or more provisions of this
     Agreement shall constitute a waiver of any other provisions hereof

f.   Successors and Assigns. All of the terms and provisions contained herein
     shall insure to the benefit of and shall be binding upon the parties hereto
     and their successors and assigns.

g.   Separate Counterparts. This document may be executed in one or more
     separate counterparts, each of which, when so executed, shall be deemed to
     be an original. Such counterparts shall together constitute and shall be
     one and the same instrument.

h.   Headings. The caption appearing at the commencement of the sections hereof
     are descriptive only and are for convenience of reference. Should there be
     any conflict between any such caption and the section at the head of which
     it appears, the substantive provisions of such section and not such
     captions shall control and govern in the construction of this document.

                                        4

<PAGE>

i.   Entire Agreement. This Agreement constitutes the entire understanding and
     agreement of the parties with respect to the subject matter of this
     Agreement, and any all prior agreements, understandings or representations
     are hereby terminated and canceled in their entirety.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date first above written.

SPARTA SURGICAL CORPORATION                     IGC OF NEW YORK CORPORATION

-------------------------------------           -----------------------------
Thomas F. Reiner, President, Chairman           Howard Schuster, President (1)
and Chief Executive Officer

-------------
     (1) In addition, Mr. Schuster is executing this document in such capacity
as may be required on behalf of any other entity with which he is affiliated
which may have an agreement with the Company which is being terminated by this
agreement.

                                       5

<PAGE>

     i.   Entire Agreement. This Agreement constitutes the entire understanding
          and agreement of the parties with respect to the subject matter of
          this Agreement, and any all prior agreements, understandings or
          representations are hereby terminated and canceled in their entirety.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date first above written.

SPARTA SURG1CAL CORPORATION                        IGC OF NEW YORK CORPORATION

/s/  Thomas F. Reiner                              /s/  Howard Schuster
-------------------------------------              -----------------------------
Thomas F. Reiner, President, Chairman              Howard Schuster, President(1)
and Chief Executive Officer

----------------
     (1) In addition, Mr. Schuster is executing this document in such capacity
as may be required on behalf of any other entity with which he is affiliated
which may have an agreement with the Company which is being terminated by this
agreement.

                                        5

<PAGE>

                           SPARTA SURGICAL CORPORATION

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT") AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED TO ANY PERSON WITHOUT THE PRIOR WRITTEN CONSENT OF SPARTA SURGICAL
CORPORATION OR IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS
WARRANT UNDER SAID ACT AND UNDER APPLICABLE STATE SECURITIES LAWS.

                          COMMON STOCK PURCHASE WARRANT
                          -----------------------------

WARRANT dated as of the 4th day of March, 1999, issued by Sparta Surgical
Corporation ("Sparta"), a Delaware corporation with offices at Bernal Corporate
Park, 7068 Koll Center Parkway, Pleasanton, California 94566 to IGC of New York
Corporation, a corporation organized under the laws of New York ("IGC")..

     This Warrant entitles IGC or its permitted assigns, to purchase from
Sparta, at any time, or from time to time, up until 5:00 p.m., United States
Eastern Standard Time on the three (3) year anniversary of the date hereof,
300,000 of Sparta's fully paid and nonassessable shares of Common Stock, $0.002
par value (the "Common Stock"), at a price of $0.95 per share (the "Exercise
Price"), subject to adjustment as provided for herein, upon the holder's
presentation and surrender of this Warrant at the corporate offices of Sparta,
and upon its payment of the Exercise Price and any applicable taxes paid either
in cash, or by certified or official bank check, payable in lawful money of the
United States of America to the order of Sparta. Notwithstanding the foregoing,
this Warrant may not be exercised! during the so-called "quiet period" following
any filing made with the United States Securities and Exchange Commission
respecting any public offering of Sparta's securities.

     1. Exercise. The purchase rights represented by this Warrant are
exercisable, at the option of the holder, in whole at any time, or in part from
time to time. In the case of the purchase of less than all of the shares
purchasable under this Warrant, Sparta shall cancel this Warrant upon the
surrender hereof and shall execute and deliver a new Warrant of like tenor for
the balance of the shares purchasable hereunder.

     2. Registration Rights. The holder of this Warrant shall have such
registration rights respecting the Common Stock for which this Warrant is
exercisable as are set forth in a Registration Rights Agreement by and between
IGC and Sparta of even date herewith (the "Registration Rights Agreement"). The
holder of this Warrant shall be subject to an Irrevocable Voting Trust Agreement
appointing Thomas F. Reiner as Trustee with full voting rights over such common
shares. Any subsequent holder of this Warrant shall be deemed to have consented
to the provisions of the Registration Rights Agreement and the Irrevocable
Voting Trust Agreement and shall be bound by the terms and conditions thereof

     3. Investment Representations. By its execution of this Warrant, IGC hereby
represents and certifies as follows:

          (i) IGC of New York Corporation is purchasing this Warrant for the
          investment of itself and its principals only, and not with a view to
          the further resale or distribution thereof

<PAGE>

                           SPARTA SURGICAL CORPORATION

          (ii) IGC of New York Corporation understands that this Warrant does
          not provide the holder with voting rights, representation on Sparta's
          Board of Directors, preemptive rights, nor any share of dividends,
          spinoffs or distributions, while this Warrant remains unexercised.

          (iii) IGC of New York Corporation has had adequate opportunity to
          investigate Sparta, and to meet with its principals and ascertain the
          nature and value of its business, purposes and prospects.

     4. Transfer Restrictions. The holder shall not transfer, assign or
otherwise dispose, directly or indirectly, of its rights or interests in the
Warrant (or in any Common Stock or other securities which may be received upon
its being exercised) in the absence of there being a registration statement in
effect with respect to these Warrants under the United States Securities Act of
1933, as amended, or applicable state law. Any purported transfer, assignment or
other purported disposition in contravention of the terms of this Warrant shall
be void and of no effect. Any certificate for shares of Common Stock issued upon
the exercise of this Warrant shall bear a legend setting forth such restrictions
on transfer.

     5. Adjustments. The number and kind of securities or other property
purchasable upon exercise of this Warrant shall be subject to adjustment from
time to time upon the occurrence, after the date hereof, of any of the following
events.

          (a) In case Sparta shall (i) pay a dividend in, or make a distribution
          of, shares of Common Stock or of capital stock convertible into Common
          Stock on its outstanding Common Stock, (ii) subdivide its outstanding
          shares of Common stock into a greater number of such shares or (iii)
          combine its outstanding shares of Common Stock into a smaller number
          of such shares, the total number of shares of Common Stock purchasable
          upon the exercise of this Warrant outstanding immediately prior
          thereto shall be adjusted so that the holder shall be entitled to
          receive at the same aggregate Exercise Price the number of shares of
          Common Stock which such holder would have owned or have been entitled
          to receive immediately following the happening of any of the events
          described above had such Warrant been exercised in full immediately
          prior to the happening of such event. Any adjustment made pursuant to
          this subsection shall, in the case of a stock dividend or
          distribution, become effective as of the record date therefor and, in
          the case of a subdivision or combination, be made as of the effective
          date thereof If, as a result of an adjustment made pursuant to this
          subsection, the holder of any Warrant thereafter surrendered for
          exercise shall become entitled to receive shares of two or more
          classes of capital stock of Sparta, the Board of Directors of Sparta
          (whose determination shall be conclusive) shall determine the
          allocation of the adjusted Exercise Price between or among shares of
          such classes of capital stock.

                                        2

<PAGE>

                           SPARTA SURGICAL CORPORATION

          (b) In the event of any adjustment of the total number of shares of
          Common Stock purchasable upon the exercise of Warrants pursuant to
          subsection (a) above, the Exercise Price of each such Warrant shall
          remain unchanged, but the number of shares of capital stock obtainable
          on exercise of each such Warrant shall be adjusted as provided in
          subsection (a) above.

          (c) In the event of a capital reorganization or a reclassification of
          the Common Stock (except as provided in subsection (a) above or
          subsection (d) below), any holder, upon exercise of Warrants, shall be
          entitled to receive, in substitution for the Common Stock to which
          such holder would have become entitled upon exercise immediately prior
          to such reorganization or reclassification, the shares (of any class
          or classes) or other securities or property of Sparta (or cash) that
          such holder would have been entitled to receive at the same aggregate
          Exercise Price upon such reorganization or reclassification if such
          Warrants had been exercised immediately prior thereto; in any such
          case, appropriate provision (as determined by the Board of Directors
          of Sparta) shall be made for the application of this Section 5 with
          respect to the rights and interests thereafter of the holders
          (including but not limited to the allocation of the Exercise Price
          between or among shares of classes of capital stock), to the end that
          this Section 5 (including the adjustments of the number of shares of
          Common Stock or other securities purchasable and the Exercise Price
          thereof) shall thereafter be reflected, as nearly as reasonably
          practicable, in all subsequent exercises of the Warrants for any
          shares or securities or other property (or cash) thereafter
          deliverable upon the exercise of the Warrants.

          (d) In case of any consolidation of Sparta with, or merger of Sparta
          into, another corporation (other than a consolidation or merger which
          does not result in any reclassification or change of the outstanding
          Common Stock), or in case of any sale or conveyance to another
          corporation of the property of Sparta as an entirety or substantially
          as an entirety, the corporation formed by such consolidation or merger
          or the corporation which shall have acquired such assets, as the case
          may be, shall execute and deliver to the holder a supplemental
          agreement providing that the holder of each Warrant then outstanding
          shall have the right thereafter (until the expiration of such Warrant)
          to receive, upon exercise of such Warrant, solely the kind and amount
          of shares of stock and other securities and property (or cash)
          receivable upon which consolidation, merger, sale or transfer by a
          holder of the number of shares of Common Stock of Sparta for which
          such Warrant might have been exercised immediately prior to such
          consolidation, merger, sale or transfer. Such supplemental agreement
          shall provide for adjustment which shall be as nearly equivalent as
          may action in respect of which indemnity may be sought against Sparta,
          IGC or such underwriter or such controlling person, as the case me be,
          will notify Sparta in writing of the commencement thereof, and,
          subject to the provisions hereinafter stated, Sparta shall assume the
          defense of such action (including the employment of counsel, who

                                        3

<PAGE>

                           SPARTA SURGICAL CORPORATION

          shall be counsel satisfactory to IGC or such underwriter or
          controlling person, as the case may be, and the payment of all
          expenses) insofar as such action shall relate to any alleged liability
          in respect of which indemnity may be sought against Sparta. IGC or any
          underwriter or any such controlling person shall have the right to
          employ separate counsel in any such action and to participate in the
          defense thereof, but the fees and expenses of such counsel shall be at
          IGC's sole expense. Sparta shall not be liable to indemnify any person
          for any settlement of any such action effected without Sparta's
          consent.

     6. Settlement of Underwriter. In the event that IGC proposes to offer any
of the Registrable Shares to or through an underwriter, IGC shall use such
underwriter, if any, as Sparta has identified as its principal investment
banker.

     7. Adjustment. If there shall be any change in the shares of Sparta through
reorganization, recapitalization, stock dividend, stock split, combination,
amalgamation or exchange of shares, or the like, all of the terms and provisions
of this Warrant shall apply to any new, additional or different shares of
investments issued with respect to the Registrable Shares as a result of such
event, and such shares or investments shall be deemed to constitute "Registrable
Shares" hereunder.

     8. Successors and Assigns. This Warrant shall be binding on and inure to
the benefit of Sparta's successors and assigns, and shall inure to the benefit
of, and be binding of, and be binding on, transferees and assignees of the
Warrants, but not transferees or assignees or Registrable Shares; and shall not
be otherwise assignable by IGC. Upon any proper transfer or exercise of the
benefits hereof, the transferee or person exercising such rights, as the case
may be, shall also be bound by the transferor's obligations hereunder, except as
otherwise expressly provided herein.

     9. Notices. Notices hereunder shall be given as follows:

In the case of notice to IGC, to:

                 IGC of New York Corporation
                 40 E. 94th Street
                 New York, NY 10128

and in the case of notice to Sparta, to:

                 Sparta Surgical Corporation
                 Bernal Corporate Park
                 7068 Koll Center Parkway, Suite, 425
                 Pleasanton, California 94566

                 Attn: Mr. Thomas F. Reiner

                                        4

<PAGE>

                           SPARTA SURGICAL CORPORATION

with a copy to:

                 Mr. John Kostrubanic
                 Pepe & Hazard, LLP
                 150 Federal Street, 28th Floor
                 Boston, Massachusetts 02110

or to such other addresses as to which the parties may subsequently  notify each
other in writing. All notices hereunder shall be in writing, and shall be deemed
to have been given at the date of actual  receipt,  or when  actual  delivery to
such address has been confirmed in writing by an unaffiliated  delivery service.
The party  responsible  for giving  notice  under any  provision of this Warrant
shall bear all expenses and fees incurred in connection therewith.

     10. Governing Law. This Warrant shall be construed in accordance with the
laws of the State of California.

     11. Amendments; Waivers. Changes, amendments or modification in or
additions to of any provisions under or of this Warrant may be made only by a
written instrument executed by the parties thereto. Waivers must be by written
instrument executed by the party to be bound thereby.

     12. Captions. Captions are for convenience only and shall not be deemed to
be a part of this Warrant, nor shall be taken into any consideration in the
interpretation hereof.

     13. Counterparts. This Warrant may be executed in any number of
counterparts, each of which shall constitute an original, but which taken
together shall constitute one instrument.

     IN WITNESS WHEREOF, the undersigned have caused this Warrant to be executed
as of the day and year first above written.

                                             SPARTA SURGICAL CORPORATION

                                             By:  /s/  Thomas F. Reiner
                                                 -------------------------------
                                                Thomas F. Reiner, President, CEO
                                                and Chairman of the Board

                                             By:
                                                 -------------------------------
                                                 Howard Schuster
                                                 IGC of New York Corporation

                                        5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]